CUE
Cue BiopharmaNASDAQ
Healthcare • Biotechnology
Updated 1 day ago
Coverage ready
Factor tilt: Anti-Quality Micro Cap
$19.57-20.48%
Close Oct 13, 2026
- Market cap
- $124.09M
- 1 month
- -35.9%
- 3 months
- -31.3%
- 1 year
- -18.0%
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$2.24Quarter to Sep 30, 2026 · 3 analysts · revenue $1.03M
- Short interest
- 10.3% of float702.2K shares · settled Sep 30, 2026 · +111.4% since Sep 15, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $37.65M
- Net income
- -$164.11M
- Free cash flow
- -$50.17M
- Book value
- $2.31M
- Total debt
- $8.81M
- P/E
- —
- Price / sales
- —
- Price / book
- —
- FCF yield
- —
- Net margin
- -435.8%
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if CUE is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: HIGH
14 top institutions tracked
as of 2026-Q2 (filed 2026-09-22)
Insider context
Sentiment: bearish
Last trade: sell 59 days ago
Red flags: 8
Largest 13-F holders · Q2 2026
49 filers reported a long position in CUE for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
Q1 2026 shares are adjusted for the 2026-04-24 1-for-30 reverse split.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Bleichroeder LP | $11.7M | 370.7K | +63.1% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $9.2M | 292.1K | New |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.1M | 161.7K | +97.4% |
| Ikarian Capital, LLC | $3.3M | 104.4K | New |
| Tetragon Partners GP Ltd | $3M | 93.8K | New |
| STEMPOINT CAPITAL LP | $2.1M | 67K | New |
| BlackRock, Inc. | $1.8M | 57.8K | +286.1% |
| ADAR1 Capital Management, LLC | $1.7M | 55.2K | New |
| Lion Point Capital, LP | $1.7M | 52.9K | -27.9% |
| Squadron Capital Management LLC | $1.6M | 50K | New |
Get the Full Analysis for CUE
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.